BriaCell Therapeutics Corp (BCTX) concluded trading on Wednesday at a closing price of $4.48, with 19.8 million shares of worth about $88.71 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -66.63% during that period and on April 16, 2025 the price saw a gain of about 19.47%. Currently the company’s common shares owned by public are about 3.71M shares, out of which, 3.47M shares are available for trading.
Stock saw a price change of 8.74% in past 5 days and over the past one month there was a price change of 15.46%. Year-to-date (YTD), BCTX shares are showing a performance of -47.14% which decreased to -87.13% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.00 but also hit the highest price of $36.60 during that period. The average intraday trading volume for BriaCell Therapeutics Corp shares is 352.85K. The stock is currently trading 11.35% above its 20-day simple moving average (SMA20), while that difference is up 12.59% for SMA50 and it goes to -50.76% lower than SMA200.
BriaCell Therapeutics Corp (NASDAQ: BCTX) currently have 3.71M outstanding shares and institutions hold larger chunk of about 12.25% of that.
The stock has a current market capitalization of $16.62M and its 3Y-monthly beta is at 1.37. It has posted earnings per share of -$5.00 in the same period. It has Quick Ratio of 1.37 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BCTX, volatility over the week remained 16.19% while standing at 11.84% over the month.
Stock’s fiscal year EPS is expected to drop by -1615.00% while it is estimated to increase by 71.43% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on February 14, 2022 offering a Buy rating for the stock and assigned a target price of $25 to it.
